does novo nordisk have a patent on semaglutide Snapshot of the Landscape Patent Expiry Day: Novo Nordisk

6.1 Lack of national epidemiological data While isolated hospital-based and regional studies have reported local prevalence rates, there is currently no national registry or longitudinal cohort that captures the full scope of MAFLD across Vietnam

Antidepressant medications: The FDA-approval process and the need for updates

Prescribing practices vary significantly across the medical community

Neurodegenerative disorders Recent research indicates that GLP-1 receptor agonists are potentially advantageous for neurodegenerative disorders (Table 2), especially in light of the recognized association between diabetes and dementia

doi: 10.1167/iovs.66.7.5, 23